"Site-restricted conjugation of native mAbs offers the best of two worlds"Read more
LinXis was founded in 2011 as the result of a collaboration between individual investors with strong experience in the (pre-) clinical development of antibodies and linker chemistry in oncology.
Since its conception, LinXis has continued to develop expertise in the field of Antibody Drug Conjugates (ADCs) and has grown its network to increase partnerships and collaborations with academic institutions such as the VU University Medical Center Amsterdam (VUmc). Together they complement each other’s know-how and LinXis can exploit VUmc in-house facilities to develop and optimize every individual stage of the ADC development and production process.
In 2015, LinXis launched a second business unit for the development of targeted non-oncological diseases, starting with a drug for the treatment of portal hypertension. Discussions have been initiated with research institutes of the universities of Bonn, Groningen and Utrecht that have state-of-the-art laboratory facilities and are well known for their (pre)clinical expertise on chronic liver diseases and portal hypertension.
LinXis has established a subcontractor network with a number of highly competent and innovative companies and university departments to cover all aspects of the pipeline, from drug development to clinical trials. This network includes IBIS Technologies, SMS-oncology, QPS and academic partners for preclinical imaging, biomolecular analysis, medical oncology and internal medicine.
LinXis has its premises at the VUmc, in the business district of Amsterdam (‘Zuidas’), The Netherlands.